The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer von Janjigian, Yelena Y., Kawazoe, Akihito, Yañez, Patricio, Li, Ning, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan S., Xu, Jianming, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shah, Sukrut, Bhagia, Pooja, Chung, Hyun Cheol

Volltext

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase... von Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol

Volltext

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus von Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O'Neill, Edward A, Engel, Samuel S, Kaufman, Keith D, Lai, Eseng

Volltext

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study von Kastelein, John J P, Prof, Besseling, Joost, MD, Shah, Sukrut, PhD, Bergeron, Jean, MD, Langslet, Gisle, MD, Hovingh, G Kees, MD, Al-Saady, Naab, MD, Koeijvoets, Michiel, BSc, Hunter, John, MS, Johnson-Levonas, Amy O, PhD, Fable, Jennifer, PharmD, Sapre, Aditi, PhD, Mitchel, Yale, MD

Volltext

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With... von Gotto, Antonio M., MD, DPhil, Cannon, Christopher P., MD, Li, Xiujiang Susie, PhD, Vaidya, Sanskruti, MS, MPhil, Kher, Uma, MS, Brinton, Eliot A., MD, Davidson, Michael, MD, Moon, Jennifer E., PhD, Shah, Sukrut, PhD, RPh, Dansky, Hayes M., MD, Mitchel, Yale, MD, Barter, Philip, MD, PhD

Volltext

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup... von Satake, Hironaga, Lee, Keun-Wook, Chung, Hyun Cheol, Lee, Jeeyun, Yamaguchi, Kensei, Chen, Jen-Shi, Yoshikawa, Takaki, Amagai, Kenji, Yeh, Kun-Huei, Goto, Masahiro, Chao, Yee, Lam, Ka-On, Han, Shi Rong, Shiratori, Shinichi, Shah, Sukrut, Shitara, Kohei

Volltext

Inhibition of intestinal cholesterol absorption by ezetimibe in humans von SUDHOP, Thomas, LÜTJOHANN, Dieter, KODAL, Annette, IGEL, Michael, TRIBBLE, Diane L, SHAH, Sukrut, PEREVOZSKAYA, Inna, VON BERGMANN, Klaus

Volltext

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S] von Davidson, Michael, Liu, Sherry Xueyu, Barter, Philip, Brinton, Eliot A., Cannon, Christopher P., Gotto, Antonio M., Leary, Elizabeth T., Shah, Sukrut, Stepanavage, Michael, Mitchel, Yale, Dansky, Hayes M.

Volltext

Lipid-modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-density Lipoprotein Cholesterol von Ballantyne, Christie M., MD, Shah, Sukrut, PhD, Kher, Uma, MS, Hunter, John A., MS, Gill, Geraldine G., MPharm, Cressman, Michael D., DO, Ashraf, Tanya B., BA, Johnson-Levonas, Amy O., PhD, Mitchel, Yale B., MD

Volltext

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib von Cannon, Christopher P., MD, Dansky, Hayes M., MD, Davidson, Michael, MD, Gotto, Antonio M., MD, DPhil, Brinton, Eliot A., MD, Gould, A. Lawrence, PhD, Stepanavage, Michael, MS, Liu, Sherry Xueyu, MS, Shah, Sukrut, RPh, PhD, Rubino, Joseph, MBA, Gibbons, Patrice, MS, Hermanowski-Vosatka, Anne, MD, PhD, Binkowitz, Bruce, PhD, Mitchel, Yale, MD, Barter, Philip, MD, PhD

Volltext

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study von Sun, Jong-Mu, Shen, Lin, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, Maqueda, Maria Alsina, Goekkurt, Eray, Hara, Hiroki, Antunes, Luis, Fountzilas, Christos, Tsuji, Akihito, Oliden, Victor Castro, Liu, Qi, Shah, Sukrut, Bhagia, Pooja, Kato, Ken

Volltext

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer von Kato, Ken, Shah, Manish A, Enzinger, Peter, Bennouna, Jaafar, Shen, Lin, Adenis, Antoine, Sun, Jong-Mu, Cho, Byoung Chul, Özgüro lu, Mustafa, Kojima, Takashi, Kostorov, Vladimir, Hierro, Cinta, Zhu, Ying, McLean, Lee Anne, Shah, Sukrut, Doi, Toshihiko

Volltext

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease von Cannon, Christopher P, Shah, Sukrut, Dansky, Hayes M, Davidson, Michael, Brinton, Eliot A, Gotto, Antonio M, Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B, Zafarino, Jennifer, Mitchel, Yale, Barter, Philip

Volltext

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study von Lee, Keun-Wook, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles S, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo R, Chao, Joseph, Wainberg, Zev A, Cao, Z Alexander, Aurora-Garg, Deepti, Kobie, Julie, Cristescu, Razvan, Bhagia, Pooja, Shah, Sukrut, Tabernero, Josep, Shitara, Kohei, Wyrwicz, Lucjan

Volltext

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 von Wainberg, Zev A., Fuchs, Charles S., Tabernero, Josep, Shitara, Kohei, Muro, Kei, Van Cutsem, Eric, Bang, Yung-Jue, Chung, Hyun Cheol, Yamaguchi, Kensei, Varga, Eniko, Chen, Jen-Shi, Hochhauser, Daniel, Thuss-Patience, Peter, Al-Batran, Salah-Eddin, Garrido, Marcelo, Kher, Uma, Shih, Chie-Schin, Shah, Sukrut, Bhagia, Pooja, Chao, Joseph

Volltext

First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress von Sun, Jong-Mu, Enzinger, Peter C., Adenis, Antoine, Shah, Manish A., Kato, Ken, Bennouna, Jaafar, Doi, Toshihiko, Hawk, Natalyn Nicole, Yu, Li, Shah, Sukrut, Bhagia, Pooja, Shen, Lin

Volltext

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

Volltext

LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma von Sun, Jong-Mu, Enzinger, Peter C., Adenis, Antoine, Shah, Manish A., Kato, Ken, Bennouna, Jaafar, Doi, Toshihiko, Hawk, Natalyn Nicole, Yu, Li, Shah, Sukrut, Bhagia, Pooja, Shen, Lin

Volltext

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer von Mansoor, Wasat, Joo, Seongjung, Norquist, Josephine M, Kato, Ken, Sun, Jong-Mu, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chol, Sunpaweravong, Patrapim, Alsina Maqueda, Maria, Goekkurt, Eray, Suryawanshi, Shailaja, Shah, Sukrut, Shen, Lin

Volltext

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590... von Metges, Jean-Philippe, Kato, Ken, Sun, Jong-Mu, Shah, Manish A., Enzinger, Peter C., Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, ALSINA, MARIA, Buchschacher, Gary L, Wu, Jimin, Shah, Sukrut, Bhagia, Pooja, Shen, Lin

Volltext